Regenxbio reports 3-year durability data for sura-vec in Phase II ALTITUDE diabetic retinopathy trial

By Public Technologies
  • Regenxbio disclosed three-year follow-up results from its Phase II ALTITUDE study of sura-vec in non-proliferative diabetic retinopathy.
  • The data were already presented at the Retina Society Annual Scientific Meeting in Los Angeles.
  • Most patients at the selected dose showed sustained disease improvement without needing additional diabetic retinopathy treatment.
  • No vision-threatening events were reported in responders; the safety profile stayed consistent over long-term follow-up.
  • The same dose is being tested in the Phase IIb/III NAAVIGATE trial, supporting a potential one-time, in-office approach.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regenxbio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609241917PR_NEWS_USPR_____PH56710) on September 24, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.